Natural Killer Cells Therapeutics Market Report by Therapeutics (NK Cell Therapies, NK Cell Directed Antibodies), Application (Cancer, Gastrointestinal Diseases, Immunoproliferative Disorders, and Others), End User (Hospitals, Research Centers and Institutes, and Others), and Region 2024-2032

Natural Killer Cells Therapeutics Market Report by Therapeutics (NK Cell Therapies, NK Cell Directed Antibodies), Application (Cancer, Gastrointestinal Diseases, Immunoproliferative Disorders, and Others), End User (Hospitals, Research Centers and Institutes, and Others), and Region 2024-2032

Report Format: PDF+Excel | Report ID: SR112024A4214
Buy Now

Global Natural Killer Cells Therapeutics Market:

The global natural killer cells therapeutics market size reached US$ 2.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 8.3 Billion by 2032, exhibiting a growth rate (CAGR) of 12.3% during 2024-2032. The rising risks of developing cancer, along with the expanding geriatric population, are propelling the market.

Report Attribute 
Key Statistics
Base Year
2023
Forecast Years
2024-2032
Historical Years
2018-2023
Market Size in 2023
US$ 2.8 Billion
Market Forecast in 2032
US$ 8.3 Billion
Market Growth Rate 2024-2032 12.3%


Natural Killer Cells Therapeutics Market Analysis:

  • Major Market Drivers: The growing number of individuals with cancer, infectious diseases, and liver disorders, on account of the lack of physical activities, unhealthy dietary patterns, and the increasing air pollution levels, is catalyzing the market.
  • Key Market Trends: Extensive investments in clinical studies that focus on tumor-targeted antibody strategies to minimize risks and toxicities are among the emerging trends fueling the market.
  • Competitive Landscape: Some of the prominent companies in the global market include Affimed GmbH, Bristol-Myers Squibb Company, Fate Therapeutics, Fortress Biotech Inc., Glycostem Therapeutics, Innate Pharma S.A., Kuur Therapeutics Inc. (Athenex Inc.), Nkarta Inc., Takeda Pharmaceutical Company Limited, and Ziopharm Oncology Inc., among many others.
  • Geographical Trends: North America exhibits a clear dominance in the market, owing to numerous financial schemes by government agencies across the region for cancer patients.
  • Challenges and Opportunities: One of the challenges hindering the market is the difficulty in manufacturing processes. This can be overcome by improving scalable production methods to ensure quality and efficacy.
     

Natural Killer Cells Therapeutics Market


Natural Killer Cells Therapeutics Market Trends:

Increasing Popularity of Combination Therapies

Combining NK cell therapies with other treatment modalities to enhance therapeutic efficacy is gaining extensive traction. For example, Innate Pharma's Lumoxiti, an anti-CD22 immunotoxin, is adopted in conjunction with NK cells to destroy and target CD22-expressing cancer cells in hairy cell leukemia. Moreover, this approach leverages the strengths of both therapies. Besides this, in May 2024, Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company developing innovative cell therapy platforms for autoimmune, cancer, and infectious diseases, introduced SNAP-CAR NK cells to target multiple antigens.

Growing Regulatory Approval

The rising focus among government agencies on enhancing the reliability and efficiency of NK cell production is acting as a significant growth-inducing factor. Furthermore, they are encouraging the translation of laboratory research into viable clinical therapies, which will continue to fuel the market over the foreseeable future. For example, in April 2024, Ingenium Therapeutics, a leading innovator in next-generation NK cell therapies, received an Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML).

Rising Demand for Real-Time Monitoring

The widespread integration of real-time monitoring and data analytics into NK cell therapy development is enhancing treatment precision and patient outcomes. Moreover, platforms like Bio-Techne's Ella system enable precise monitoring of cytokine production during NK cell expansion, thereby ensuring optimal cell functionality. Real-time analytics also allow researchers to adjust culture conditions dynamically, which aids in improving the quality and effectiveness of the NK cells produced. This is positively influencing the market.

Global Natural Killer Cells Therapeutics Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with the natural killer cells therapeutics market forecast at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on therapeutics, application, and end user.

Breakup by Therapeutics:

  • NK Cell Therapies
  • NK Cell Directed Antibodies
     

Currently, NK cell directed antibodies hold the majority of the total market share

The report has provided a detailed breakup and analysis of the market based on the therapeutics. This includes NK cell therapies and NK cell directed antibodies. According to the report, NK cell directed antibodies represented the largest market segmentation.

NK cell directed antibodies target natural killer cells to enhance their ability to recognize and destroy cancer cells. For example, Affimed's AFM13, a bispecific NK cell engager, targets CD30 on cancer cells and CD16A on NK cells.

Breakup by Application:

  • Cancer 
  • Gastrointestinal Diseases
  • Immunoproliferative Disorders
  • Others
     

Cancer currently exhibits a clear dominance in the market

The report has provided a detailed breakup and analysis of the market based on the application. This includes cancer, gastrointestinal diseases, immunoproliferative disorders, and others. According to the report, cancer represented the largest market segmentation.

The inflating need for effective cancer treatments drives the segment's growth. Recent product launches have underscored the potential of NK cell-based therapies in oncology. For instance, Fate Therapeutics' FT596 is an off-the-shelf, iPSC-derived NK cell therapy designed to target multiple cancer types, including B-cell malignancies.

Breakup by End User:

  • Hospitals
  • Research Centers and Institutes 
  • Others
     

Currently, research centers and institutes hold the majority of the total market share

The report has provided a detailed breakup and analysis of the market based on the end user. This includes hospitals, research centers and institutes, and others. According to the report, research centers and institutes represented the largest market segmentation.

Research centers and institutes offer high-quality reagents and technologies that streamline NK cell research, which is increasing the natural killer cells therapeutics market share. For example, Bio-Techne's Cloudz Human NK Cell Expansion Kit allows researchers to expand NK cells ex vivo efficiently.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa
     

North America exhibits a clear dominance in the market

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

Advancements in biotechnology and a strong focus on innovative cancer treatments are primarily catalyzing the market in North America. According to the IMARC, the United States cancer immunotherapy market size is projected to exhibit a growth rate (CAGR) of 10.90% during 2024-2032. Besides this, collaborations between biotech firms are strengthening the regional market.

Competitive Landscape:

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major market companies have also been provided. Some of the key players in the market include:

  • Affimed GmbH
  • Bristol-Myers Squibb Company
  • Fate Therapeutics
  • Fortress Biotech Inc.
  • Glycostem Therapeutics
  • Innate Pharma S.A.
  • Kuur Therapeutics Inc. (Athenex Inc.)
  • Nkarta Inc.
  • Takeda Pharmaceutical Company Limited
  • Ziopharm Oncology Inc.
     

 (Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

 Natural Killer Cells Therapeutics Market Recent Developments:

  • May 2024: Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company developing innovative cell therapy platforms for autoimmune, cancer, and infectious diseases, introduced SNAP-CAR NK cells to target multiple antigens.
  • April 2024: Ingenium Therapeutics, a leading innovator in next-generation NK cell therapies, received an Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML).
  • January 2024: Indapta Therapeutics, Inc., a privately held biotechnology company developing IDP-023, a natural killer (NK) cell therapeutics for the treatment of cancer, announced the treatment of the first patients in its Phase 1 trial in multiple myeloma and non-Hodgkin’s lymphoma.


Natural Killer Cells Therapeutics Market Report Scope:

Report Features Details
Base Year of the Analysis 2023
Historical Period 2018-2023
Forecast Period 2024-2032
Units US$ Billion
Scope of the Report Exploration of Historical Trends and Market Outlook, Industry Catalysts and Challenges, Segment-Wise Historical and Predictive Market Assessment:
  • Therapeutics
  • Application
  • End User
  • Region
Therapeutics Covered NK Cell Therapies, NK Cell Directed Antibodies
Applications Covered Cancer, Gastrointestinal Diseases, Immunoproliferative Disorders, Others
End Users Covered Hospitals, Research Centers and Institutes, Others
Regions Covered Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered Affimed GmbH, Bristol-Myers Squibb Company, Fate Therapeutics, Fortress Biotech Inc., Glycostem Therapeutics, Innate Pharma S.A., Kuur Therapeutics Inc. (Athenex Inc.), Nkarta Inc., Takeda Pharmaceutical Company Limited, Ziopharm Oncology Inc., etc.
Customization Scope 10% Free Customization
Report Price and Purchase Option Single User License: US$ 3899
Five User License: US$ 4899
Corporate License: US$ 5899
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)


Key Benefits for Stakeholders:

  • IMARC's industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the natural killer cells therapeutics market from 2018-2032.
  • The research report provides the latest information on the market drivers, challenges, and opportunities in the global natural killer cells therapeutics market.
  • The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
  • Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the natural killer cells therapeutics industry and its attractiveness.
  • The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.

Key Questions Answered in This Report

The global natural killer cells therapeutics market was valued at US$ 2.8 Billion in 2023.

We expect the global natural killer cells therapeutics market to exhibit a CAGR of 12.3% during 2024-2032.

The continuous development of novel methods and technologies by various healthcare organizations for boosting the immune response of cancer patients through allogeneic, off-the-shelf NK cell-based therapies, is primarily driving the global natural killer cells therapeutics market.

The sudden outbreak of the COVID-19 pandemic has led to the rising demand for natural killer cells therapeutics for emergency treatment of mild-to-moderate coronavirus infection, thereby positively impacting the global market.

Based on the therapeutics, the global natural killer cells therapeutics market can be segmented into NK cell therapies and NK cell directed antibodies. Currently, NK cell directed antibodies hold the majority of the total market share.

Based on the application, the global natural killer cells therapeutics market has been divided into cancer, gastrointestinal diseases, immunoproliferative disorders, and others. Among these, cancer currently exhibits a clear dominance in the market.

Based on the end user, the global natural killer cells therapeutics market can be categorized into hospitals, research centers and institutes, and others. Currently, research centers and institutes account for the largest market share.

On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.

Some of the major players in the global natural killer cells therapeutics market include Affimed GmbH, Bristol-Myers Squibb Company, Fate Therapeutics, Fortress Biotech Inc., Glycostem Therapeutics, Innate Pharma S.A., Kuur Therapeutics Inc. (Athenex Inc.), Nkarta Inc., Takeda Pharmaceutical Company Limited, and Ziopharm Oncology Inc.

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Natural Killer Cells Therapeutics Market Report by Therapeutics (NK Cell Therapies, NK Cell Directed Antibodies), Application (Cancer, Gastrointestinal Diseases, Immunoproliferative Disorders, and Others), End User (Hospitals, Research Centers and Institutes, and Others), and Region 2024-2032
Purchase options




Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Get in Touch With Us
UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials

Aktive Services

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

Read More
Greenfish S.A.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

Read More
Colruyt Group

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Read More
KRISHAK BHARATI CO-OP LTD

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

Read More
Zee Media Corp. Ltd.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Read More
Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

Read More
Sumitomo Corporation

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

Read More
Hameln Rds

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

Read More
Quality Consultants BV

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

Read More
TATA Advanced Systems Limited

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

Read More
Stax

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

Read More
DEinternational Egypt

IMARC did an outstanding job in preparing our study. They were punctual and precise, delivering all the data we required in a clear and well-organized format. Their attention to detail and ability to meet deadlines was impressive, making them a reliable partner for our project.

Read More